Upcoming Change Reflects the Company’s Focus on Oral Delivery of Biotherapeutics
SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will change its name to Biora Therapeutics, Inc. during the second quarter of 2022, to better reflect the company’s focus on developing its pipeline for targeted and systemic oral delivery of biotherapeutics.
“As we complete our strategic transformation, we are launching Biora Therapeutics to reflect our mission going forward, which is to reimagine therapeutics and their delivery,” said Adi Mohanty, Chief Executive Officer. “By creating innovative smart pills designed for targeted drug delivery to the GI tract and for systemic, needle-free delivery of biotherapeutics, we are developing therapies to improve patients’ lives.”
Progenity expects the brand launch for Biora Therapeutics™ to coincide with the company’s Q1 2022 earnings call in May, and the company’s NASDAQ ticker symbol will also change from “PROG” to “BIOR” at that time. No action is needed from current stockholders. The company’s Class A common stock will continue to be listed on NASDAQ and the CUSIP will not change. The legal name change is expected to be completed on or about April 26, 2022, upon satisfying all applicable requirements.
For updates about Biora Therapeutics, please follow @BioraThera on Twitter.
About Progenity
Progenity, Inc. is a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics and is developing a suite of investigational ingestible devices designed to provide precise drug delivery solutions and diagnostic sampling. Progenity will become Biora Therapeutics, Inc. during the second quarter of 2022.
For more information visit www.progenity.com, or follow the company on LinkedIn or Twitter.
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
ir@progenity.com
(917) 741-7792
Media Contact
Kristin Schaeffer
CG Life
media@progenity.com
(858) 457-2436
CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…
MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…
Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…
PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…